News Wire

The American Academy of Neurology (AAN) has updated its 2008 guidelines on the use of botulinum toxin for spasticity, cervical dystonia, blepharospasm, and migraine headache, based on recent research. The revised guidelines were published online in the April 18 issue of Neurology.

A five-year study has shown that stereotactic body radiation therapy (SBRT) to treat prostate cancer offers a higher cure rate than more traditional approaches, according to researchers at the University of Texas Southwestern Medical Center.

The number of potentially deadly infections from contaminated medical scopes is far higher than what federal officials previously estimated, according to a report from Kaiser Health News.

Chances are that outpatient chemotherapy treatment costs are higher if a patient’s oncologist works for a health care system than if the physician has his or her own practice, according to a study by researchers at the University of Chicago.

The FDA has approved a supplemental new drug application (sNDA) for afatinib (Gilotrif, Boehringer Ingelheim) for the treatment of patients with advanced squamous cell carcinoma of the lung whose disease has progressed after treatment with platinum-based chemotherapy. Afatinib, an oral, once-daily epidermal growth factor receptor (EGFR)-directed therapy, is currently approved in the U.S.

After eight weeks of treatment, 97% to 98% of genotype 1 to 3 (GT1–3) chronic hepatitis C virus (HCV)-infected patients without cirrhosis treated with an investigational, once-daily, ribavirin (RBV)-free, pan-genotypic regimen of ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor (AbbVie), achieved a sustained virological response at 12 weeks post-treatment (SVR12)

More than 60 nonprofit groups and medical experts have sent a letter to the Joint Commission, a nonprofit agency that accredits U.S. hospitals, asking it to revisit its standards for pain management. Only hospitals that have been accredited can receive payments from government plans, such as Medicare and Medicaid, making the group’s standards highly influential.

Results have been reported from the C-EDGE Head-to-Head trial, a comparative, phase 3, open-label study evaluating the efficacy and safety of Zepatier (elbasvir and grazoprevir, Merck) 50-mg/100-mg tablets versus a regimen of sofosbuvir 400-mg tablets plus peginterferon and ribavirin (pegIFN/RBV) in treatment-naïve and pegIFN/RBV treatment-experienced patients with chronic hepatitis C virus (HC

Oncolytics Biotech has announced updated results from a randomized phase 2 study of Reolysin, a proprietary variant of the reovirus, in combination with carboplatin and paclitaxel in patients with metastatic pancreatic cancer. The study was sponsored by the National Cancer Institute (NCI).

A large study from Kaiser Permanente, involving more than seven million adults, found significant differences in the diagnosis and treatment of mental health conditions based on the race and ethnicity of the patients.

Women live longer in areas with more green vegetation, according to research funded by the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health. Women with the highest levels of vegetation, or greenness, near their homes had a 12% lower death rate compared to women with the lowest levels of vegetation near their homes.

Annual spending on prescription medications in the United States will increase 22% over the next five years, climbing as high as $400 billion by 2020, according to a new report from IMS Health Holdings, a health care information company.

In a letter dated March 18, officials at the Centers for Medicare and Medicaid Services (CMS) proposed banning Theranos Inc. founder Elizabeth Holmes and the company’s president, Sunny Balwani, from owning blood-testing laboratories for at least two years after determining that Theranos failed to fix problems at its California lab, according to an article in the Wall Street Journal.

Scientists at the Centers for Disease Control and Prevention (CDC) have concluded, after a review of existing evidence, that Zika virus is a cause of microcephaly and other severe fetal brain defects. The study findings were published in the New England Journal of Medicine.

The FDA has accepted a supplemental biologics license application that seeks to expand the use of nivolumab (Opdivo, Bristol-Myers Squibb) to include patients with classical Hodgkin’s lymphoma (cHL) after prior therapies. The application included data from the CheckMate-205 trial, which evaluated nivolumab in cHL patients who received autologous stem cell transplant and brentuximab vedotin.